Of the few pre­clin­i­cal IPOs, Metageno­mi keeps de­tails about IND plans close

There’s no word yet on when Metageno­mi will en­ter the clin­ic.

In its first quar­ter­ly up­date as a pub­lic com­pa­ny, the Cal­i­for­nia biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA